Vistagen Therapeutics Inc (VTGN) FinancialsVTGNVistagen Therapeutics Inc

Evaluating the bottom line, Vistagen Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -904.34%, while the net margin is -882.79%. These profitability ratios, combined with a Return on Equity (ROE) of -166.46%, provide a clear picture of how effectively VTGN converts its operational activities into shareholder value.

In the context of the broader market, VTGN competes directly with industry leaders such as TCRT and FBLG. With a market capitalization of $7.30M, it holds a leading position in the sector. When comparing efficiency, VTGN's gross margin of 100.00% stands against TCRT's N/A and FBLG's N/A. Such benchmarking helps identify whether Vistagen Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Vistagen's financial performance shows a revenue increase to $1.27 million, but the company continues to report substantial net losses, including $13 million in the latest quarter. The gross margin remains at 100%, but this is overshadowed by the negative net income and declining equity.